NEW YORK (AP) - In a story September 29, 2020, which included information about Myovant Sciences’ potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study. The drug failed to meet one of its goals within a broader late-stage study.
Please read our comment policy before commenting.